Clinical practice guideline on bladder cancer (Part I)
UroPrecision · 2023
DOI: 10.1002/uro2.11 ↗Kurz gefasst
Leitlinie in der Zeitschrift UroPrecision, 2023. Verfasst von Xiying Dong und 18 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bladder cancer represents one of the most prevalent malignant tumors affecting the urinary system. As per data disclosed by the National Cancer Registration Center of China in 2019, the incidence of bladder cancer was 5.80 per 100,000 in 2015, placing it as the thirteenth most common systemic malignancy. Bladder cancer poses a substantial threat to public health in China, underlining the critical importance of standardizing diagnosis and treatment to enhance clinical outcomes. This clinical practice guideline for bladder cancer centers on the etiologies, clinical presentations, and diagnostic procedures for suspected bladder cancer, in addition to the histopathology and staging of urothelial bladder cancer.
Zitieren
APA
Dong, X., Song, G., Guan, K., Wang, T., Feng, X., Liu, Y., Liu, M., Ji, Z., Li, X., Li, J., Zhang, Y., Zhou, F., Zhou, A., Xu, W., Xu, T., Gao, X., Zhai, Q., Wei, Q., & Xing, N. (2023). Clinical practice guideline on bladder cancer (Part I). UroPrecision. https://doi.org/10.1002/uro2.11
Vancouver
Dong X, Song G, Guan K, Wang T, Feng X, Liu Y, et al. Clinical practice guideline on bladder cancer (Part I). UroPrecision. 2023. doi:10.1002/uro2.11
BibTeX
@article{Dong2023,
author = {Dong, Xiying and Song, Gang and Guan, Kaopeng and Wang, Tie and Feng, Xiaoli and Liu, Yulin and Liu, Min and Ji, Zhigang and Li, Xiao and Li, Jiongming and Zhang, Yong and Zhou, Fangjian and Zhou, Aiping and Xu, Wanhai and Xu, Tao and Gao, Xianshu and Zhai, Qing and Wei, Qiang and Xing, Nianzeng},
title = {Clinical practice guideline on bladder cancer (Part I)},
journal = {UroPrecision},
year = {2023},
doi = {10.1002/uro2.11}
}
EUVIMED